Skip to main content

Table 5 Multivariate analyses (cox regression) of relapse-free survival and overall survival a

From: Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia

Variables Relapse-free survival Overall survival
  95% CI    95% CI  
HR Lower Upper P HR Lower Upper P
Whole cohort (n = 86)         
Ageb 3.083 0.184 51.762 0.434 3.252 1.322 8.002 0.010*
NPM1 c 0.087 0.012 0.604 0.014* 0.392 0.128 1.195 0.100
FLT3- ITDd 21.079 1.427 311.302 0.026* 4.532 1.395 14.723 0.012*
FLT3- TKD 19.630 1.539 250.445 0.022* 1.801 0.184 17.603 0.613
CEBPA e 0.408 0.144 1.154 0.091 0.398 0.147 1.080 0.070
IDH1 c 0.448 0.039 5.167 0.520 0.648 0.128 3.268 0.599
IDH2 c 0.583 0.025 13.640 0.737 0.254 0.036 1.781 0.168
DNMT3A c 0.292 0.041 2.098 0.221 0.731 0.158 3.380 0.689
MLL c 31.310 0.729 1344.29 0.073 1.040 0.215 5.020 0.961
MN1 1.391 1.027 1.883 0.033* 1.195 1.025 1.394 0.023*
ERG 5.799 0.548 61.325 0.144 2.545 0.993 6.520 0.052
miR-181a 0.824 0.598 1.135 0.236 0.860 0.692 1.069 0.174
miR-3151 1.183 0.750 1.867 0.469 1.285 0.884 1.866 0.189
BDH2 f 2.035 0.472 8.782 0.341 2.547 1.094 6.685 0.050*
  1. Abbreviations: HR indicates Hazard ratio; CI, confidence interval.
  2. aOnly patients with intensive induction chemotherapy enrolled.
  3. bAge > 60 relative to Age ≤ 60 (the reference).
  4. cNPM1mut versus NPM1wild type; ID H1mut versus IDH1wild type; IDH2mut versus IDH2wild type; DNMT3Amut versus DNMT3Awild type ; MLLmut versus MLLwild.
  5. dFLT3- ITDmut versus FLT3- ITDneg.
  6. eCEBPAdouble-mutation versus CEBPAsingle mutation versus CEBPAno mutation.
  7. fBDH2high relative to BDH2low group.
  8. *Statistically significant (P < 0.05).